Education
About Us
Working with TipRanks
Follow Us
Camurus AB (CAMRF)
OTHER OTC:CAMRF
CAMRF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.90 - $73.25
Previous CloseN/A
Volume89.00
Average Volume (3M)0.00
Market Cap
$3.42B
Enterprise Value$31.05B
Total Cash (Recent Filing)kr56.00K
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)86.7
Beta0.56
Next Earnings
May 15, 2025EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding58,879,017
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.62
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$66.72Price Target Upside8.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Camurus AB News
PremiumCompany Announcements
Camurus AB Reports Strong Growth in 2024
PremiumPre-Earnings
Is CAMRF a Buy, Before Earnings?
PremiumCompany Announcements
Camurus AB Reports Strong Q3 Results and Raises Outlook
PremiumPre-Earnings
Is CAMRF a Buy, Before Earnings?---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.66% Mutual Funds
― Other Institutional Investors
95.19% Public Companies and
Individual Investors
CAMRF FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was $39.90 and its highest was $73.25 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is $3.42B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is May 15, 2025 which is in 20 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Feb 13, 2025. The company reported $0.256 earnings per share for the quarter, beating the consensus estimate of $0.194 by $0.062.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 0.31.
How many shares outstanding does Camurus AB have?
Camurus AB has 58,879,017 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of $0.256 in its last earnings report, beating expectations of $0.194. Following the earnings report the stock price went up 4.989%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in CAMRF
---
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
---
CAMRF Company Deck
---
CAMRF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.Read More>---
CAMRF Stock 12 Month Forecast
Average Price Target
$66.72
▲(8.49% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioArctic AB Class B
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Best Analysts Covering CAMRF
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
+44.87%
reiterated a buy rating 6 months ago
Copying Brian Balchin's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +44.87% per trade.
---